{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:35:00Z","timestamp":1764858900824},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s13277-016-5205-9","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T07:32:02Z","timestamp":1470987122000},"page":"14117-14128","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-\u03baB target genes"],"prefix":"10.1007","volume":"37","author":[{"given":"Elham","family":"Farhadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Zaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Safa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"issue":"12","key":"5205_CR1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O\u2019Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913\u201323.","journal-title":"Ann Intern Med"},{"issue":"1","key":"5205_CR2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.181.1.307","volume":"181","author":"CL Sawyers","year":"1995","unstructured":"Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;181(1):307\u201313.","journal-title":"J Exp Med"},{"issue":"20","key":"5205_CR3","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J. 1997;16(20):6151\u201361.","journal-title":"EMBO J"},{"issue":"10","key":"5205_CR4","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","volume":"159","author":"SK Chai","year":"1997","unstructured":"Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159(10):4720\u20138.","journal-title":"J Immunol"},{"issue":"8","key":"5205_CR5","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","volume":"118","author":"GV Helgason","year":"2011","unstructured":"Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood. 2011;118(8):2035\u201343.","journal-title":"Blood"},{"issue":"4","key":"5205_CR6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000140633","volume":"119","author":"JM Goldman","year":"2008","unstructured":"Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia\u2014how does it work? Acta Haematol. 2008;119(4):212\u20137.","journal-title":"Acta Haematol"},{"issue":"9","key":"5205_CR7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG, Antman KH. Imatinib mesylate\u2014a new oral targeted therapy. N Engl J Med. 2002;346(9):683\u201393.","journal-title":"N Engl J Med"},{"key":"5205_CR8","doi-asserted-by":"crossref","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876\u2013880.","DOI":"10.1126\/science.1062538"},{"issue":"4","key":"5205_CR9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1034\/j.1600-0609.2000.065004258.x","volume":"65","author":"R Saffroy","year":"2000","unstructured":"Saffroy R, Lemoine A, Brezillon P, Frenoy N, Delmas B, Goldschmidt E, et al. Real-time quantitation of bcr-abl transcripts in haematological malignancies. Eur J Haematol. 2000;65(4):258\u201366.","journal-title":"Eur J Haematol"},{"issue":"2","key":"5205_CR10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","volume":"64","author":"NJ Donato","year":"2004","unstructured":"Donato NJ, JY W, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004;64(2):672\u20137.","journal-title":"Cancer Res"},{"issue":"43","key":"5205_CR11","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001;20(43):6188\u201395.","journal-title":"Oncogene"},{"issue":"47","key":"5205_CR12","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21(47):7137\u201346.","journal-title":"Oncogene"},{"issue":"6","key":"5205_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","volume":"105","author":"M Chen","year":"2013","unstructured":"Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst. 2013;105(6):405\u201323.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"5205_CR14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","volume":"28","author":"AK Samanta","year":"2009","unstructured":"Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28(14):1669\u201381.","journal-title":"Oncogene"},{"issue":"2","key":"5205_CR15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nsmb.1552","volume":"16","author":"S Gu","year":"2009","unstructured":"Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3\u2032 untranslated region in mammalian mRNAs. Nat Struct Mol Biol. 2009;16(2):144\u201350.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"5205_CR16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","volume":"9","author":"W Filipowicz","year":"2008","unstructured":"Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102\u201314.","journal-title":"Nat Rev Genet"},{"issue":"7006","key":"5205_CR17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","volume":"431","author":"V Ambros","year":"2004","unstructured":"Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350\u20135.","journal-title":"Nature"},{"issue":"1","key":"5205_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PPO.0b013e318164145e","volume":"14","author":"M Fabbri","year":"2008","unstructured":"Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J. 2008;14(1):1\u20136.","journal-title":"Cancer J"},{"issue":"1","key":"5205_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-07-0573","volume":"7","author":"PE Blower","year":"2008","unstructured":"Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7(1):1\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"5205_CR20","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1535-7163.MCT-09-0127","volume":"8","author":"E Salerno","year":"2009","unstructured":"Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H, et al. Correcting miR-15a\/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther. 2009;8(9):2684\u201392.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"5205_CR21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","volume":"360","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 2015;360(2):245\u201356.","journal-title":"Cancer Lett"},{"key":"5205_CR22","doi-asserted-by":"crossref","unstructured":"Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012:3e436.","DOI":"10.1038\/cddis.2012.175"},{"issue":"12","key":"5205_CR23","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s11095-011-0547-x","volume":"28","author":"A Semaan","year":"2011","unstructured":"Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, et al. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)\/cip(1)). Pharm Res. 2011;28(12):3079\u201390.","journal-title":"Pharm Res"},{"issue":"2","key":"5205_CR24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2011.220","volume":"105","author":"J Buechner","year":"2011","unstructured":"Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, et al. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011;105(2):296\u2013303.","journal-title":"Br J Cancer"},{"issue":"12","key":"5205_CR25","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1158\/0008-5472.CAN-11-3546","volume":"72","author":"G Ren","year":"2012","unstructured":"Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012;72(12):3091\u2013104.","journal-title":"Cancer Res"},{"issue":"22","key":"5205_CR26","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1111\/febs.12013","volume":"279","author":"XP He","year":"2012","unstructured":"He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, et al. Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. Febs J. 2012;279(22):4201\u201312.","journal-title":"Febs J"},{"issue":"3","key":"5205_CR27","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jhep.2013.10.028","volume":"60","author":"L Xu","year":"2014","unstructured":"Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2014;60(3):590\u20138.","journal-title":"J Hepatol"},{"issue":"2","key":"5205_CR28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000363010","volume":"34","author":"L Wang","year":"2014","unstructured":"Wang L, Li L, Guo R, Li X, Lu Y, Guan X, et al. miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. Cell Physiol Biochem. 2014;34(2):413\u201322.","journal-title":"Cell Physiol Biochem"},{"issue":"23","key":"5205_CR29","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/bioinformatics\/btp565","volume":"25","author":"P Alexiou","year":"2009","unstructured":"Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M, Hatzigeorgiou AG. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics. 2009;25(23):3049\u201355.","journal-title":"Bioinformatics"},{"issue":"2","key":"5205_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/156652411794859250","volume":"11","author":"TM Witkos","year":"2011","unstructured":"Witkos TM, Koscianska E, Krzyzosiak WJ. Practical aspects of microRNA target prediction. Curr Mol Med. 2011;11(2):93\u2013109.","journal-title":"Curr Mol Med"},{"issue":"6","key":"5205_CR31","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","volume":"70","author":"CL Sawyers","year":"1992","unstructured":"Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70(6):901\u201310.","journal-title":"Cell"},{"issue":"5","key":"5205_CR32","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1007\/s11033-010-0439-x","volume":"38","author":"A Wojtyla","year":"2011","unstructured":"Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep. 2011;38(5):3339\u201349.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"5205_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1383-5742(99)00091-5","volume":"462","author":"C Cerni","year":"2000","unstructured":"Cerni C. Telomeres, telomerase, and myc. An update. Mutat Res. 2000;462(1):31\u201347.","journal-title":"Mutat Res"},{"issue":"3","key":"5205_CR34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"N Carlesso","year":"1996","unstructured":"Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J Exp Med. 1996;183(3):811\u201320.","journal-title":"J Exp Med"},{"issue":"1","key":"5205_CR35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12185-015-1797-x","volume":"102","author":"S CL","year":"2015","unstructured":"CL S, Deng TR, Shang Z, Xiao Y. JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression. Int J Hematol. 2015;102(1):76\u201385.","journal-title":"Int J Hematol"},{"issue":"14","key":"5205_CR36","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.83.14.5214","volume":"83","author":"Y Tsujimoto","year":"1986","unstructured":"Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986;83(14):5214\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"5205_CR37","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117(12):3409\u201320.","journal-title":"Blood"},{"issue":"7","key":"5205_CR38","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","volume":"12","author":"JY Reuther","year":"1998","unstructured":"Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12(7):968\u201381.","journal-title":"Genes Dev"},{"issue":"6847","key":"5205_CR39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/35088074","volume":"412","author":"M Digicaylioglu","year":"2001","unstructured":"Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412(6847):641\u20137.","journal-title":"Nature"},{"issue":"51","key":"5205_CR40","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1038\/sj.onc.1209942","volume":"25","author":"DS Basseres","year":"2006","unstructured":"Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817\u201330.","journal-title":"Oncogene"},{"issue":"1","key":"5205_CR41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"5205_CR42","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","volume":"66","author":"AK Samanta","year":"2006","unstructured":"Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468\u201372.","journal-title":"Cancer Res"},{"issue":"3","key":"5205_CR43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1042\/BJ20101585","volume":"434","author":"N Patel","year":"2011","unstructured":"Patel N, Tahara SM, Malik P, Kalra VK. Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J. 2011;434(3):473\u201382.","journal-title":"Biochem J"},{"issue":"6","key":"5205_CR44","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.7314\/APJCP.2013.14.6.3503","volume":"14","author":"N Pouladi","year":"2013","unstructured":"Pouladi N, Kouhsari SM, Feizi MH, Gavgani RR, Azarfam P. Overlapping region of p53\/wrap53 transcripts: mutational analysis and sequence similarity with microRNA-4732-5p. Asian Pac J Cancer Prev. 2013;14(6):3503\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5908","key":"5205_CR45","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1126\/science.1165395","volume":"322","author":"S Varambally","year":"2008","unstructured":"Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322(5908):1695\u20139.","journal-title":"Science"},{"issue":"18","key":"5205_CR46","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1128\/JVI.00961-08","volume":"82","author":"FZ Wang","year":"2008","unstructured":"Wang FZ, Weber F, Croce C, Liu CG, Liao X, Pellett PE. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J Virol. 2008;82(18):9065\u201374.","journal-title":"J Virol"},{"issue":"10","key":"5205_CR47","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.bjc.6602592","volume":"92","author":"O Uziel","year":"2005","unstructured":"Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005;92(10):1881\u201391.","journal-title":"Br J Cancer"},{"issue":"11","key":"5205_CR48","first-page":"3341","volume":"8","author":"T Tauchi","year":"2002","unstructured":"Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res. 2002;8(11):3341\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5205_CR49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<172::AID-IJC12>3.0.CO;2-8","volume":"89","author":"A Latil","year":"2000","unstructured":"Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M, Lidereau R, et al. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer. 2000;89(2):172\u20136.","journal-title":"Int J Cancer"},{"issue":"3","key":"5205_CR50","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1006\/bbrc.1997.7806","volume":"241","author":"K Fujimoto","year":"1997","unstructured":"Fujimoto K, Takahashi M. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem Biophys Res Commun. 1997;241(3):775\u201381.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7092","key":"5205_CR51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431\u20136.","journal-title":"Nature"},{"issue":"3","key":"5205_CR52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI11991","volume":"107","author":"AS Baldwin","year":"2001","unstructured":"Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107(3):241\u20136.","journal-title":"J Clin Invest"},{"issue":"6","key":"5205_CR53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ceb.2003.10.005","volume":"15","author":"E Burstein","year":"2003","unstructured":"Burstein E, Duckett CS. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol. 2003;15(6):732\u20137.","journal-title":"Curr Opin Cell Biol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5205-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-016-5205-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5205-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T21:08:50Z","timestamp":1718744930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-016-5205-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["5205"],"URL":"https:\/\/doi.org\/10.1007\/s13277-016-5205-9","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]}}}